[Press release] COVID-19: mass screening reveals significant transmission risk from asymptomatic carriers
Based on the results of the large-scale testing programme run in Luxembourg, researchers show that asymptomatic SARS-CoV-2 carriers represent an important vector for transmission.
Towards personalised treatment of recurrent brain tumours
On February 25th, Prof Simone Niclou, Director of the LIH Department of Oncology (DONC) and group leader of the NORLUX Neuro-Oncology Laboratory, was awarded a EUR 850,000 check by the Fondation Cancer and the Luxembourg National Research Fund (FNR) in support of the GLASS-LUX study.
Important support to LIH cancer research
On February 25th, three LIH group leaders from the Department of Oncology (DONC) were awarded a symbolic check by the Fondation Cancer and the Luxembourg National Research Fund (FNR) in support of their cancer research projects.
Hypertension: know what is behind your numbers
High blood pressure (HBP) or hypertension is often called the ‘‘silent killer’’, due to the lack of obvious symptoms indicating its presence. It is therefore important to be able to self-monitor one’s blood pressure and understand how to interpret the measurements. To this end, the Cardiovascular Research Unit (CVRU) of the LIH Department of Population Health (DoPH) recently published an informative brochure to help shed light into cardiovascular health.
Industrial partnerships with Pharma to strengthen translational research at LIH
The Tumor Immunotherapy and Microenvironment (TIME) research group of the LIH Department of Oncology (DONC) teamed up with Swedish Pharma company Sprint Bioscience to investigate the therapeutic benefit of small molecules inhibiting key pathways in cancer cells. The aim is to potentiate the effectiveness of immunotherapy and providing innovative and translational approaches to treating several cancers.
[Press release] Novel immunotherapy approach to treat cat allergy
Researchers from the Department of Infection and Immunity of the Luxembourg Institute of Health (LIH) brought forward the potential of high doses of a specific adjuvant molecule, namely CpG oligonucleotide, in successfully modulating the immune system’s allergic response to the main cat allergen Fel d 1, thereby inducing a tolerance-promoting reaction and reverting the main hallmarks of cat allergy. The researchers analysed the molecular mechanisms underlying this tolerance and proposed a pre-clinical allergen-specific immunotherapy approach to improve the treatment and control of this common type of allergy. The full study results were published very recently in the renowned international journal “Allergy”, the official journal of the European Academy of Allergy and Clinical Immunology (EAACI) and one of the top two journals worldwide in the allergy field.
Physical activity in Luxembourg: how active are we?
On January 27th, the Global Observatory for Physical Activity (GoPA!) released its second round of physical activity country profiles, presenting detailed information on physical activity research, policy and surveillance in 162 countries across the world. The Physical Activity, Sport and Health research group of the LIH Department of Population Health (DoPH) was the point of contact for the 2020 Country Card for Luxembourg, contributing with the data and information generated through past population studies in order to give an overview of the country’s performance in this domain.
Training the next generation of translational scientists
On February 1st, the new i2TRON (Integrating immune strategies for Translational Research in Oncology and Neurology) research and training programme for PhD candidates officially started. Its overarching goal is to develop the ability of doctoral candidates to successfully translate fundamental research findings into innovative pre-clinical and clinical applications, thereby contributing to shaping the next generation of translational researchers and to developing advanced medicine and care.
Targeted proteomics for personalised medicine at LIH
The field of proteomics, i.e. the characterisation of the complete pool of proteins produced by a cell, is acquiring increasing importance in understanding the onset of various diseases and devising new personalised treatments. At LIH, this area is being explored by Prof Gunnar Dittmar and his team at the Proteomics of Cellular Signaling research group of the Quantitative Biology Unit (QBU). His work has resulted in the publication of his 100th scientific paper in the January 2021 issue of the prestigious international journal “Analytical Chemistry”. In this interview, Prof Dittmar discusses his expertise and research focus.